Latest News

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Three finalist pharmacies shared the mindsets, tools, and community-rooted strategies driving their operational success and patient-centered care.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Oncology pharmacists step into precision care—tracking mRNA vaccines, frailty-guided supportive therapy, NGS actionability, and new thoracic targets.

Two pharmacy owners share real-world strategies for integrating artificial intelligence (AI) and automation to boost efficiency, expand clinical capacity, and elevate patient care.

New GI cancer data highlight emerging targeted therapies, ctDNA-guided surveillance, and pharmacist-led workflows to boost outcomes.

The Moderna mRNA influenza vaccine won the FDA panel vote, but ACIP turmoil and a legal fight could threaten its fall 2026 rollout.

As multimodal analgesia and novel therapies such as suzetrigine expand treatment options, non-opioid approaches are playing an increasingly important role in acute pain management while helping reduce reliance on opioids.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Pharmacy technicians are uniquely positioned to shape patient experience.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

New breast cancer trial insights reshape metastatic care: sacituzumab benefits broadly, oral SERDs lag, denosumab every 12 weeks suffices.

From artificial intelligence (AI)-driven dispensing to specialty service diversification, Jaime Montuoro, PharmD, previews the education lineup at McKesson ideaShare 2026.

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.

McKesson ideaShare 2026 brings independent pharmacy's premier gathering to Denver, June 18-21, with Pharmacy Times on-site for exclusive interviews and coverage.

Minimal residual disease (MRD) negativity exceeded 90% with 100% response and no progression in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

With this approval, Capvaxive is the only PCV specifically indicated and studied in the US for use in this patient population.

Fixed-duration pirtobrutinib plus venetoclax-rituximab reduced the risk of progression or death by 45% and achieved higher undetectable MRD rates than venetoclax-rituximab alone.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

FDA approval of the first generic version of baloxavir marboxil brings an affordable single-dose flu treatment, boosting access for the 2026-27 influenza season.